Literature DB >> 25734072

The estrogen receptor fusion system in mouse models: a reversible switch.

Jonathan Whitfield1, Trevor Littlewood2, Gerard I Evan2, Laura Soucek1.   

Abstract

Reversible regulatory mouse models have significantly contributed to our understanding of normal tissue and cancer biology, providing the opportunity to temporally control initiation, progression, and evolution of physiological and pathological events. The tamoxifen inducible system, one of the best-characterized "reversible switch" models, has a number of beneficial features. In this system, the hormone-binding domain of the mammalian estrogen receptor is used as a heterologous regulatory domain. Upon ligand binding, the receptor is released from its inhibitory complex and the fusion protein becomes functional. We summarize the advantages and drawbacks of the system, describe several mouse models that rely on it, and discuss potential improvements that could render it even more useful and versatile.
© 2015 Cold Spring Harbor Laboratory Press.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25734072      PMCID: PMC6768801          DOI: 10.1101/pdb.top069815

Source DB:  PubMed          Journal:  Cold Spring Harb Protoc        ISSN: 1559-6095


  29 in total

1.  Steroid-binding domains for regulating the functions of heterologous proteins in cis.

Authors:  D Picard
Journal:  Trends Cell Biol       Date:  1993-08       Impact factor: 20.808

2.  Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation.

Authors:  Yuval Dor; Juliana Brown; Olga I Martinez; Douglas A Melton
Journal:  Nature       Date:  2004-05-06       Impact factor: 49.962

3.  Directed evolution of specific receptor-ligand pairs for use in the creation of gene switches.

Authors:  Karuppiah Chockalingam; Zhilei Chen; John A Katzenellenbogen; Huimin Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-05       Impact factor: 11.205

4.  Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases.

Authors:  A K Indra; X Warot; J Brocard; J M Bornert; J H Xiao; P Chambon; D Metzger
Journal:  Nucleic Acids Res       Date:  1999-11-15       Impact factor: 16.971

5.  Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion.

Authors:  S Pelengaris; T Littlewood; M Khan; G Elia; G Evan
Journal:  Mol Cell       Date:  1999-05       Impact factor: 17.970

6.  Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression.

Authors:  Stella Pelengaris; Michael Khan; Gerard I Evan
Journal:  Cell       Date:  2002-05-03       Impact factor: 41.582

7.  Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse.

Authors:  Shigemi Hayashi; Andrew P McMahon
Journal:  Dev Biol       Date:  2002-04-15       Impact factor: 3.582

8.  Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycER mice.

Authors:  K Blyth; M Stewart; M Bell; C James; G Evan; J C Neil; E R Cameron
Journal:  Oncogene       Date:  2000-02-10       Impact factor: 9.867

9.  Generation and characterization of transgenic mice expressing tamoxifen-inducible cre-fusion protein specifically in mouse liver.

Authors:  Huan-Zhang Zhu; Jian-Quan Chen; Guo-Xiang Cheng; Jing-Lun Xue
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

10.  Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

Authors:  Zeruesenay Desta; Bryan A Ward; Nadia V Soukhova; David A Flockhart
Journal:  J Pharmacol Exp Ther       Date:  2004-05-24       Impact factor: 4.030

View more
  8 in total

Review 1.  Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies.

Authors:  Kelsie L Becklin; Garrett M Draper; Rebecca A Madden; Mitchell G Kluesner; Tomoyuki Koga; Miller Huang; William A Weiss; Logan G Spector; David A Largaespada; Branden S Moriarity; Beau R Webber
Journal:  CRISPR J       Date:  2022-08

2.  Cyanine Photocages Enable Spatial Control of Inducible Cre-Mediated Recombination.

Authors:  Alexander P Gorka; Tsuyoshi Yamamoto; Jianjian Zhu; Martin J Schnermann
Journal:  Chembiochem       Date:  2018-04-16       Impact factor: 3.164

3.  Tamoxifen administration to mice.

Authors:  Jonathan Whitfield; Trevor Littlewood; Laura Soucek
Journal:  Cold Spring Harb Protoc       Date:  2015-03-02

4.  Reversible modulation of SIRT1 activity in a mouse strain.

Authors:  Katherine V Clark-Knowles; Xiaohong He; Karen Jardine; Josée Coulombe; Danielle Dewar-Darch; Annabelle Z Caron; Douglas A Gray; Michael W McBurney
Journal:  PLoS One       Date:  2017-03-08       Impact factor: 3.240

5.  The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening of telomeres (ALT).

Authors:  Robert Lu; Julienne J O'Rourke; Alexander P Sobinoff; Joshua A M Allen; Christopher B Nelson; Christopher G Tomlinson; Michael Lee; Roger R Reddel; Andrew J Deans; Hilda A Pickett
Journal:  Nat Commun       Date:  2019-05-28       Impact factor: 14.919

6.  Activation of creER recombinase in the mouse calvaria induces local recombination without effects on distant skeletal segments.

Authors:  Jue Hou; Charles P Lin; Giuseppe Intini
Journal:  Sci Rep       Date:  2021-04-15       Impact factor: 4.379

7.  The Akt Forkhead Box O Transcription Factor Axis Regulates Human Cytomegalovirus Replication.

Authors:  Hongbo Zhang; Anthony J Domma; Felicia D Goodrum; Nathaniel J Moorman; Jeremy P Kamil
Journal:  mBio       Date:  2022-08-10       Impact factor: 7.786

Review 8.  Off and back-on again: a tumor suppressor's tale.

Authors:  Jonuelle Acosta; Walter Wang; David M Feldser
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.